125 related articles for article (PubMed ID: 34846682)
1. Speed of response to dopaminergic agents in prolactinomas.
Hage C; Salvatori R
Endocrine; 2022 Mar; 75(3):883-888. PubMed ID: 34846682
[TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
[TBL] [Abstract][Full Text] [Related]
3. Giant prolactinomas, a detailed analysis of 196 adult cases.
Lisa B; Arno V; Christophe B; Heyning Paul V; Carlien H
Pituitary; 2023 Oct; 26(5):529-537. PubMed ID: 37544978
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas.
Wildemberg LE; Fialho C; Gadelha MR
Presse Med; 2021 Dec; 50(4):104080. PubMed ID: 34687915
[TBL] [Abstract][Full Text] [Related]
5. The Prolactin per Unit Tumor Volume Ratio Accurately Distinguishes Prolactinomas From Secondary Hyperprolactinemia due to Stalk Effect.
Faje A; Jones P; Swearingen B; Tritos NA
Endocr Pract; 2022 Jun; 28(6):572-577. PubMed ID: 35339688
[TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia after menopause: Diagnosis and management.
Auriemma RS; Pirchio R; Pivonello R; Colao A
Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.
Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A
Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567
[TBL] [Abstract][Full Text] [Related]
8. [Hyperprolactinemia in the postmenopause: versions and contraversions].
Leshchenko OY
Ter Arkh; 2021 Oct; 93(10):1234-1239. PubMed ID: 36286827
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Dopamine Agonist Therapy Withdrawal in Children with Prolactinomas.
Almutlaq N; Eugster EA; Nabhan Z; Donegan D
Horm Res Paediatr; 2022; 95(3):291-295. PubMed ID: 35609555
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of prolactin and the role of dopamine agonists: A review.
Kirsch P; Kunadia J; Shah S; Agrawal N
Front Endocrinol (Lausanne); 2022; 13():1002320. PubMed ID: 36246929
[TBL] [Abstract][Full Text] [Related]
11. GIANT PROLACTINOMA. A CASE REPORT.
Šulavíková Z; Krásnik V
Cesk Slov Oftalmol; 2023; 79(3):143-148. PubMed ID: 37344216
[TBL] [Abstract][Full Text] [Related]
12. Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review.
Paracha A; Durrani U; Vasireddy S; Abid A; Waheed F; Thomure M
J Psychiatr Pract; 2024 May; 30(3):200-211. PubMed ID: 38819244
[TBL] [Abstract][Full Text] [Related]
13. Serum Prolactin Level to Tumor Size Ratio as a Potential Parameter for Preoperative Differentiation of Prolactinomas from Hyperprolactinemia-Causing Non-functional Pituitary Adenomas.
Kim JH; Hur KY; Hong SD; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2022 Mar; 159():e488-e496. PubMed ID: 34958988
[TBL] [Abstract][Full Text] [Related]
14. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
Heneghan LJ; Tsang A; Dimino C; Khandji AG; Panigrahi SK; Page-Wilson G
J Clin Endocrinol Metab; 2024 Jan; 109(2):e667-e674. PubMed ID: 37715962
[TBL] [Abstract][Full Text] [Related]
15. Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men.
Rudman Y; Duskin-Bitan H; Richter I; Tsvetov G; Masri-Iraqi H; Akirov A; Shimon I
Andrology; 2023 Oct; 11(7):1398-1407. PubMed ID: 36897756
[TBL] [Abstract][Full Text] [Related]
16. Invasive Giant Prolactinoma.
Alkhaibary A; Alharbi A; Khairy S
World Neurosurg; 2024 Jan; 181():21-22. PubMed ID: 37827431
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.
Wang L; Wang X; Gong F; Pan H; Zhu H
Front Endocrinol (Lausanne); 2023; 14():1285477. PubMed ID: 38093965
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
Benetti-Pinto CL; Prestes Nácul A; Rosa-E-Silva ACJS; Maciel GAR; Dos Santos Nunes Nogueira V; Condé Lamparelli Elias P; Martins M; Kasuki L; Mendes Garmes H; Glezer A
Arch Endocrinol Metab; 2024 Apr; 68():e230504. PubMed ID: 38578473
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
Petersenn S; Fleseriu M; Casanueva FF; Giustina A; Biermasz N; Biller BMK; Bronstein M; Chanson P; Fukuoka H; Gadelha M; Greenman Y; Gurnell M; Ho KKY; Honegger J; Ioachimescu AG; Kaiser UB; Karavitaki N; Katznelson L; Lodish M; Maiter D; Marcus HJ; McCormack A; Molitch M; Muir CA; Neggers S; Pereira AM; Pivonello R; Post K; Raverot G; Salvatori R; Samson SL; Shimon I; Spencer-Segal J; Vila G; Wass J; Melmed S
Nat Rev Endocrinol; 2023 Dec; 19(12):722-740. PubMed ID: 37670148
[TBL] [Abstract][Full Text] [Related]
20. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
